Actinomycetes: potential bio-resource for human welfare: A review (original) (raw)
Related papers
Diversity and Versatility of Actinomycetes and its Role in Antibiotic Production
2013
Article history: Received on: 06/06/2013 Revised on: 27/06/2013 Accepted on: 14/08/2013 Available online: 18/09/2013 This review summarizes about the actinomycetes and their capability to produce bioactive secondary metabolites, many of which have been successfully isolated and turned into useful drugs and other organic chemicals. Microbial pathogens are becoming increasingly resistant to available treatments so new antibiotics are needed, but the channel of compounds under development is scarce. There is frantic need of new microbial agents to fight against the antibiotic resistant strains of pathogenic microorganisms, which are rapidly increasing gradually. Therefore, actinomycetes hold a prominent position due to their diversity and proven ability to produce new bioactive compounds predominantly used in antibiotic production. A critical element in a drug discovery based on microbial extracts is the isolation of unexploited groups of microorganisms that are at the same time good p...
Actinomycetes: a yet inexhaustive source of bioactive secondary metabolites
2013
The rapid emergence of antimicrobial resistance among pathogens has led to a renewed interest to search for novel antimicrobial agents. The history of new drug discovery processes shows that novel skeletons have, in the majority of cases come from natural sources. This involves screening of microorganisms or plant extracts. They have been the source of, or inspiration for the development of chemical entities introduced as pharmaceutical. Among microorganisms, actinomycetes are enthralling resource due to their ability to produce novel bioactive secondary metabolites with antimicrobial activities. They have proven to be an inexhaustive mine of antimicrobial agents, especially those potent against pathogenic organisms. Microbial secondary metabolites, especially those from actinomycetes have been a phenomenal success for the discovery of novel drugs. They produce a wide range of secondary metabolites and more than 70% of the naturally derived antibiotics are currently in clinical use. They remain a fundamental source of new chemical diversity and an important part of drug discovery. Their ingenuity and immense industrial value is extremely noteworthy. The discovery of Streptomycin from actinomycetes has been imperative to the exploration of this group as a source of novel bioactive compounds. This group of organisms have produce antibiotics in different classes such as aminoglycosides, ansamycins, anthracyclines, glycopeptides, β-lactams, macrolides, nucleosides, peptides, polyenes, polyethers, and tetracyclines. Existence of actinomycetes has been reported in both terrestrial and marine habitats. This chapter highlight the bioactive metabolites produces by actinomycetes and their mode of action.
FEBS Letters, 2012
Actinomycetes are a rich source for the synthesis of medically and technically useful natural products. The genes encoding the enzymes for their biosynthesis are normally organized in gene clusters, which include also the information for resistance (in the case of antibacterial compounds), regulation, and transport. This facilitates the manipulation of such pathways by molecular genetic techniques. Recent advances in DNA sequencing and analytical chemistry revealed that not only new strains isolated from yet unexplored habitats, but also already known strains possess a large potential for the synthesis of novel compounds. Synthetic Biology now offers a new perspective to exploit this potential further by generating novel pathways, and thereby novel products, by combining different biosynthetic steps originating from different bacteria. The supply of precursors, which are subsequently incorporated into the final product, is often already organized in a modular manner in nature and may directly be exploited for Synthetic Biology. Here we report examples for the synthesis of building blocks and possibilities to modify and optimize antibiotic biosynthesis, exemplary for the synthesis of the manipulation of the synthesis of the glycopeptide antibiotic balhimycin. (W. Wohlleben). FEBS Letters xxx (2012) xxx-xxx j o u r n a l h o m e p a g e : w w w . F E B S L e t t e r s . o r g Please cite this article in press as: Wohlleben, W., et al. Synthetic Biology of secondary metabolite biosynthesis in actinomycetes: Engineering precursor supply as a way to optimize antibiotic production. FEBS Lett. (2012), http://dx.
Reappraisal of actinomycetes for novel bioactive metabolites
Annals of Phytomedicine: An International Journal, 2017
The appearance of new deadly diseases like cancer and the burgeoning problem of drug resistance among common bacteria l pathogens are a serious threat to a vailable trea tments. Since the channels of compounds under development are limited, this necessitates the discovery of new drugs. It is where actinomycetes can complement in the accomplishment of development of thera peu tically new bioactive compounds, predomina ntly u sed in antibiotic production. Actinomycetes are diverse in their location and have proven ability to produce new bioactive compounds. By employing modern microbiological and molecular technologies, the target-directed search for detection and isolation of bioactive actinomycetes is gaining more strength. Therefore, the innova tive isolation of actinomycetes from extreme ecosystems, their identification and cultivation using novel techniques are imperative to pursue for drug discovery.
New Dimensions of Research on Actinomycetes: Quest for Next Generation Antibiotics
Frontiers in Microbiology, 2016
Starting with the discovery of streptomycin, the promise of natural products research on actinomycetes has been captivating researchers and offered an array of lifesaving antibiotics. However, most of the actinomycetes have received a little attention of researchers beyond isolation and activity screening. Noticeable gaps in genomic information and associated biosynthetic potential of actinomycetes are mainly the reasons for this situation, which has led to a decline in the discovery rate of novel antibiotics. Recent insights gained from genome mining have revealed a massive existence of previously unrecognized biosynthetic potential in actinomycetes. Successive developments in next-generation sequencing, genome editing, analytical separation and high-resolution spectroscopic methods have reinvigorated interest on such actinomycetes and opened new avenues for the discovery of natural and naturalinspired antibiotics. This article describes the new dimensions that have driven the ongoing resurgence of research on actinomycetes with historical background since the commencement in 1940, for the attention of worldwide researchers. Coupled with increasing advancement in molecular and analytical tools and techniques, the discovery of next-generation antibiotics could be possible by revisiting the untapped potential of actinomycetes from different natural sources.
Characterization Of Actinomycetes Producing Novel Antibiotics
Biolife, 2023
Actinomycetes that may have good potential of producing novel antibiotics against coal mine soil MMKK2 gram positive bacteria most of the isolates (46%) also showed antimicrobial activity Streptomyces rochei. These bacteria are known capable of producing secondary and primary metabolites isolation and characterization of actinomycetes were conducted by serial dilution, pour plate method on GAAM, SCA Medias while characterization was by determining morphological, physiological, ecological and genetic analysis of colonies, cell structure and biochemical tests. The results solved by 16SrDNA sequence analysis showing Antibiotic activity related to the genus Streptomyces followed by Microbacterium, Agromyces, Bacillus megaterium, rare antibacterial genera accounted for minor proportions
Current approaches to exploit actinomycetes as a source of novel natural products
Journal of Industrial Microbiology & Biotechnology, 2011
For decades, microbial natural products have been one of the major sources of novel drugs for pharmaceutical companies, and today all evidence suggests that novel molecules with potential therapeutic applications are still waiting to be discovered from these natural sources, especially from actinomycetes. Any appropriate exploitation of the chemical diversity of these microbial sources relies on proper understanding of their biological diversity and other related key factors that maximize the possibility of successful identification of novel molecules. Without doubt, the discovery of platensimycin has shown that microbial natural products can continue to deliver novel scaffolds if appropriate tools are put in place to reveal them in a cost-effective manner. Whereas today innovative technologies involving exploitation of uncultivated environmental diversity, together with chemical biology and in silico approaches, are seeing rapid development in natural products research, maximization of the chances of exploiting chemical diversity from microbial collections is still essential for novel drug discovery. This work provides an overview of the integrated approaches developed at the former Basic Research Center of Merck Sharp and Dohme in Spain to exploit the diversity and biosynthetic potential of actinomycetes, and includes some examples of those that were successfully applied to the discovery of novel antibiotics.